Growth hormone treatment in patients with ataxia telangiectasia

References

• Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AMR. 2009. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat 30:1222–1230.
   PubMed Web of Science ®Google Scholar
• Boder E, Sedgwick RP. 1958. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 21:526–554.
   PubMed Web of Science ®Google Scholar
• Boder E. 1985. Ataxia-telangiectasia: an overview. Kroc Found Ser 19:1–63.
   PubMedGoogle Scholar
• Carel J-C, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J. 2012. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 97:416–425.
   PubMed Web of Science ®Google Scholar
• Chrzanowska KH, Szarras-Czapnik M, Gajdulewicz M, Kalina MA, Gajtko-Metera M, Walewska-Wolf M, Szufladowicz-Wozniak J, et al. 2010. High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study. J Clin Endocrinol Metab 95:3133–3140.
   PubMed Web of Science ®Google Scholar
• Ehlayel M, Soliman A, De Sanctis V. 2014. Linear growth and endocrine function in children with ataxia telangiectasia. Indian J Endocrinol Metab 18(Suppl 1):S93–S96.
   Google Scholar
• Esposito A, Capalbo D, De Martino L, Rezzuto M, Di Mase R, Pignata C, Salerno M. 2016. Long-term effects of growth hormone (GH) replacement therapy on hematopoiesis in a large cohort of children with GH deficiency. Endocrine 53:192–198.
   PubMed Web of Science ®Google Scholar
• Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, Ersoy F, et al. 1988. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 336:577–580.
   PubMed Web of Science ®Google Scholar
• Gershanik JJ, James V. 1971. Ataxia telangiectasia and growth failure. Am J Dis Child 1960 122:538–540.
   PubMedGoogle Scholar
• Giri N, Batista DL, Alter BP, Stratakis CA. 2007. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 92:2624–2631.
   PubMed Web of Science ®Google Scholar
• Keane J, Tajouri L, Gray B. 2015. The effect of recombinant human growth hormone and insulin-like growth factor-1 on the mitochondrial function and viability of peripheral blood mononuclear cells in vitro. Appl Physiol Nutr Metab Physiol Appl Nutr Metab 40:105–115.
   PubMed Web of Science ®Google Scholar
• Keller C, Keller KR, Shew SB, Plon SE. 1999. Growth deficiency and malnutrition in Bloom syndrome. J Pediatr 134:472–479.
   PubMed Web of Science ®Google Scholar
• Kieslich M, Hoche F, Reichenbach J, Weidauer S, Porto L, Vlaho S, Schubert R, Zielen S. 2010. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum Lond Engl 9:190–197.
   PubMed Web of Science ®Google Scholar
• Knoch J, Kamenisch Y, Kubisch C, Berneburg M. 2012. Rare hereditary diseases with defects in DNA-repair. Eur J Dermatol EJD 22:443–455.
   PubMed Web of Science ®Google Scholar
• Lavin MF. 2008. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759–769.
   PubMed Web of Science ®Google Scholar
• Liu W, Jiang Z, Wang X, Shu H, Cui W, Wilmore DW. 2003. Impact of perioperative treatment of recombinant human growth hormone on cell immune function and intestinal barrier function: randomized, double-blind, controlled trial. World J Surg 27:412–415.
   PubMed Web of Science ®Google Scholar
• Martatch AS, Doment HM, Ropelato MG, Jasper HG, Pennisi PA, Escobar ME, Heinrich JJ. 2000. Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab 85:4168–4172.
   PubMed Web of Science ®Google Scholar
• Micol R, Ben Slama L, Suarez F, Le Mignot L, Beautt J, Mahlaoui N, Dubois d'Enghien C, et al. 2011. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol 128:382muno–3e1.
   Web of Science ®Google Scholar
• Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, et al. 2002. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS Lond Engl 16:1103–1111.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, Lahad A, Sarouk I, Modan-Moses D. 2016. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res 79:889–894.
   PubMed Web of Science ®Google Scholar
• Nordan UZ, Humbert JR, MacGillivray MH, Fitzpatrick JE. 1979. Fanconi's anemia with growth hormone deficiency. Am J Dis Child 1960 133:291–293.
   PubMedGoogle Scholar
• Notarangelo L, Casanova J-L, Fischer A, Puck J, Rosen F, Seger R, Geha R; International Union of Immunological Societies Primary Immunodeficiency diseases classification committee. 2004. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 114:677–687.
   PubMed Web of Science ®Google Scholar
• Olivieri C, Danesino C, Scappaticci S, Bozzola M. 2004. Can GH induce chromosome breaks or microsatellite instability in GH-deficient children? J Endocrinol Invest 27:308–310.
   PubMed Web of Science ®Google Scholar
• Petryk A, Kanakatti Shankar R, Giri N, Hollenberg AN, Rutter MM, Nathan B, Lodish M, et al. 2015. Endocrine disorders in Fanconi anemia: recommendations for screening and treatment. J Clin Endocrinol Metab 100:803–811.
   PubMed Web of Science ®Google Scholar
• Pommerening H, van Dullemen S, Kieslich M, Schubert R, Zielen S, Voss S. 2015. Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study. Orphanet J Rare Dis 10:155.
   PubMed Web of Science ®Google Scholar
• Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. 1995. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4:2025–2032.
   PubMed Web of Science ®Google Scholar
• Schubert R, Reichenbach J, Zielen S. 2005. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol 140:517–519.
   PubMed Web of Science ®Google Scholar
• Schubert R, Schmitz N, Pietzner J, Tandi C, Theisen A, Dresel R, Christmann M, Zielen S. 2009. Growth hormone supplementation increased latency to tumourigenesis in Atm-deficient mice. Growth Factors Chur Switz 27:265–273.
   PubMed Web of Science ®Google Scholar
• Slyper AH, Shadley JD, van Tuinen P, Richton SM, Hoffmann RG, Wyatt DT. 2000. A study of chromosomal aberrations and chromosomal fragility after recombinant growth hormone treatment. Pediatr Res 47:634–639.
   PubMed Web of Science ®Google Scholar
• Taylor AM. 2001. Chromosome instability syndromes. Best Pract Res Clin Haematol 14:631–644.
   PubMed Web of Science ®Google Scholar
• Thaker V, Haagensen AL, Carter B, Fedorowicz Z, Houston BW. 2015. Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database Syst Rev CD008901.
   PubMed Web of Science ®Google Scholar
• Voss S, Pietzner J, Hoche F, Taylor AMR, Last JI, Schubert R, Zielen S. 2014. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors Chur Switz 32:123–129.
   PubMed Web of Science ®Google Scholar
• Wajnrajch MP, Gertner JM, Huma Z, Popovic J, Lin K, Verlander PC, Batish SD, et al. 2001. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics 107:744–754.
   PubMed Web of Science ®Google Scholar
• Welniak LA, Sun R, Murphy WJ. 2002. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol 71:381–387.
   PubMed Web of Science ®Google Scholar
• Wolska-Kuh B, Gregorek H, Chrzanowska K, Pirzano B, Pietrucha B, Heropolitańska-Pliszka E, Pac M, et al. 2015. Nijmegen breakage syndrome: clinical and immunological features, long-term outcome and treatment options: a retrospective analysis. J Clin Immunol 35:538–549.
   PubMed Web of Science ®Google Scholar